TTI-101 is an orally bioavailable, small-molecule inhibitor of signal transducer and activator of transcription 3 (STAT3), a transcription factor whose upregulation and activation governs many hallmarks of cancer, inflammation, and fibrosis. Preclinically, TTI-101 has demonstrated an excellent pharmacokinetic profile, potency in inhibiting STAT3 activation, and efficacy in inhibiting tumor growth in xenograft and syngeneic tumor models. In its first-in-man Phase 1 trial conducted in patients with relapsed/refractory tumors, TTI-101 monotherapy was well-tolerated and had clinical activity across a broad range of tumors including multiple durable radiographic objective responses.

For more information on the ongoing clinical trials of TTI-101, please visit our clinical trials page.

TTI-109 is Tvardi’s newest STAT3 inhibitor and has completed IND-enabling studies. TTI-109 is structurally related to, yet chemically distinct from TTI-101, and has demonstrated key characteristics for clinical use including tolerability, bioavailability, and potency.